Join the Acute Lymphoblastic Leukemia group to help and get support from people like you.
Acute Lymphoblastic Leukemia News
Measurable Residual Disease Results After Consolidation Therapy Predictive of Relapse in Pediatric Leukemia
TUESDAY, Sept. 24, 2024 – For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for...
Genetic Subtype, Genomic Alterations Linked to Relapse in Leukemia
THURSDAY, Aug. 22, 2024 – Genetic subtype, aneuploidy patterns, and genomic alterations are associated with the risk for relapse in childhood acute lymphoblastic leukemia (ALL), according to a study...
Blinatumomab + Chemo Ups Survival in B-Cell Precursor Acute Lymphoblastic Leukemia
MONDAY, July 29, 2024 – For adult patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who have measurable residual disease (MRD)-negative remission, blinatumomab in addition to...
Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
WEDNESDAY, July 17, 2024 – Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the...
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Iclusig (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
OSAKA, Japan and CAMBRIDGE, Massachusetts, March 19, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug A...
FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor...
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 – Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin...
Children With Down Syndrome More Vulnerable to Leukemia
WEDNESDAY, Nov. 1, 2023 – While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as much. These young people are at increased risk...
FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Conversion From Accelerated to Full Approval Reinforces Blincyto as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission THOUSAND OAKS, Calif., June 21, 2023...
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Rylaze dosing options provide sustained asparaginase activity throughout the entire course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma ...
U.S. FDA Approves Kite’s Tecartus as the First and Only CAR-T for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
SANTA MONICA, Calif.--(BUSINESS WIRE) October 01, 2021 – Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has granted approval for Tecartus® ...
FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi...
Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to ...
FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent...
FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
March 29, 2018 – The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL)...